Amivantamab for advanced brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called amivantamab for people with advanced brain tumors, including glioblastoma. It aims to see if the drug can shrink or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years or older.
- You have a type of advanced brain tumor called glioblastoma or a related high-grade glioma.
- Your tumor must have been confirmed by a biopsy or surgery.
- You must have had standard treatment like surgery and chemo-radiation and your tumor has come back (relapsed), or you have minimal disease left after initial treatment.
- You must be well enough to carry out daily activities (performance status 0-1) and have a life expectancy of at least 12 weeks.
- Your blood counts and organ function must be within certain limits (e.g., adequate kidney, liver, and bone marrow function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
Hear when a new Malignant Primary Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.